Articles tagged with Myeloid Leukemia
Research suggests that more intense therapies lead to better remission rates and longer survival for adults with acute myeloid leukemia (AML) who have normal genetic makeup. Patients with an enlarged spleen are less likely to enter remission, highlighting the need for targeted treatment.
A recent study published in Cancer Epidemiology, Biomarkers and Prevention journal found that obesity is associated with a higher risk of acute myeloid leukemia (AML) in older women. The study followed over 37,000 Iowa women for 14 years and found that those who were overweight or obese had a 90% increased risk of developing AML compar...
A new analysis has found a link between breastfeeding and lower risks of both acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) in children. The study suggests that even short-term breastfeeding may be protective, particularly during the first few months.
A recent study led by Dr. Ardeshir Ghavamzadeh and Dr. Kamran Alimoghaddam found that arsenic achieved complete remission in over 90% of newly diagnosed APL patients. The treatment has also shown promising results in other cancers like multiple myeloma, with a mean survival time of nearly 34 months for most patients.
A new study reveals gene microarray technology can accurately diagnose acute myeloid leukemia subtypes, leading to better treatments. The signatures of gene expression identified in pediatric leukemias also apply to adult cases, improving diagnosis and treatment outcomes.
Researchers found that AML patients with abnormal chromosomes during remission are more likely to relapse and have a shorter survival. This suggests that routine testing for chromosomal abnormalities may be necessary to predict long-term outcomes in these patients.
A retrospective study of 110 elderly leukemia patients found similar complete remission and two-year survival rates as younger patients when treated with anthracyclin-based induction chemotherapy. The study's findings suggest that age is not a predictor of survival, but rather the treatment protocol received.
Researchers have identified two distinct patterns of gene activity that correlate with patient outcomes in intermediate-risk AML. The findings could lead to more personalized treatment approaches for patients with this type of cancer.
The calcium-sensing receptor plays a crucial role in regulating mammary gland function, influencing milk production and composition. This study demonstrates that the receptor helps match milk production with available calcium levels in the mother's body.
A recent study identified 35 genes that may be linked to prognosis in pediatric acute myeloid leukemia (AML), providing new insights into the disease. These unexpected genes were found independently of current classification methods and separated patients into high- and low-risk groups.
Research suggests that a mutation in a tyrosine kinase receptor gene, when combined with aml1-eto gene mutation, can cause acute myeloid leukemia in mice. This discovery raises the possibility of new treatments targeting these genes to control the disease.
Researchers induce leukemia cells to change behavior and stimulate immune system, killing significant numbers of leukemia cells in a 3-step process. The approach has shown strong killing effect against AML cell lines but not other types of cancer, with potential for safe transfer back into patients.
Two new drugs, PKC412 and CT53518, have shown promising results in treating acute myeloid leukemia (AML), a deadly form of blood cancer. The drugs, which target the FLT3 receptor, have been effective in killing leukemia cells and prolonging survival in mouse models.
Researchers have developed a new drug, CEP-701, that targets the genetic error causing a type of leukemia. The drug has shown promising results in clinical trials, interfering with the signal of the altered gene and leading to leukemia cell death.
The European Commission has designated Mylotarg as an orphan medicinal product for treating patients with CD33-positive relapsed acute myeloid leukemia. The compound represents a novel anticancer therapy and has shown promising results in clinical trials.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
A new experimental compound, CMA-676, demonstrates promising efficacy in treating acute myelogenous leukemia (AML) with an antibody-targeted chemotherapy approach. The treatment shows a remission rate of approximately 40% comparable to standard combination chemotherapy regimens.
Clinical trials show substantial increase in leukemia-free survival among AML patients treated with Maxamine Therapy. The treatment has been shown to prevent relapse and prolong remission while maintaining a good quality of life.
A 15-year study of 628 AML patients confirms that chromosomal abnormalities can predict treatment success and likelihood of cure. Patients with specific genetic markers tend to have better outcomes, while those without them face poorer survival rates.
Researchers discovered a genetic defect in ALL1 gene duplication that signals poor prognosis and shorter survival time in AML patients. Patients with this defect require aggressive treatment, including allogenic bone marrow transplant, to improve survival rates.